About this item:

82 Views | 30 Downloads

Author Notes:

Ernest Ramsay Camp, ramsay.camp@bcm.edu

Harinarayanan Janakiraman, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Validation, Writing – original draft, Writing – review & editing, Scott A. Becker, Data curation, Formal analysis, Methodology, Alexandra Bradshaw, Methodology, Mark P. Rubinstein, Formal analysis, Resources, Writing – review & editing, and Ernest Ramsay Camp, Conceptualization, Funding acquisition, Resources, Supervision, Writing – original draft, Writing – review & editing

Marzena Swiderska-Syn provided technical assistance for this research work.

Subjects:

Research Funding:

This work was supported in part by funding from MERIT REVIEW AWARD (Issue date: 1/15/2019) Department of Veteran Affairs and Clinical Science Research and Development (1l01CX001880-01A1) for the research project titled “Targeting Sphingosine-1-phosphate to overcome SNAI1-mediated therapy” issued to C.E.R. Supported in part by the Translational Science Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313). Supported in part by the Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, Medical University of South Carolina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Keywords:

  • cancer

Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model

Journal Title:

PLoS One

Volume:

Volume 17, Number 9

Publisher:

Type of Work:

Article | Final Publisher PDF

Abstract:

The use of humanized mouse models for oncology is rapidly expanding. Autologous patient-derived systems are particularly attractive as they can model the human cancer’s heterogeneity and immune microenvironment. In this study, we developed an autologous humanized mouse cancer model by engrafting NSG mice with patient-derived xenografts and infused matched peripheral blood mononuclear cells (PBMCs). We first defined the time course of xenogeneic graft-versus-host-disease (xGVHD) and determined that only minimal xGVHD was observed for up to 8 weeks. Next, colorectal and pancreatic cancer patient-derived xenograft bearing NSG mice were infused with 5x106 human PBMCS for development of the humanized cancer models (iPDX). Early after infusion of human PBMCs, iPDX mice demonstrated engraftment of human CD4+ and CD8+ T cells in the blood of both colorectal and pancreatic cancer patient-derived models that persisted for up to 8 weeks. At the end of the experiment, iPDX xenografts maintained the features of the primary human tumor including tumor grade and cell type. The iPDX tumors demonstrated infiltration of human CD3+ cells with high PD-1 expression although we observed significant intra and inter- model variability. In summary, the iPDX models reproduced key features of the corresponding human tumor. The observed variability and high PD-1 expression are important considerations that need to be addressed in order to develop a reproducible model system.

Copyright information:

© 2022 Janakiraman et al

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote